Documents

Strong H1 2026 growth, margin gains, and robust cash flow; 2026 guidance reaffirmed.

Growth driven by health trends, innovation, and digital transformation, with strong future outlook.

Q1 2026 sales grew +2.7% like-for-like, with strong resilience and strategic portfolio moves.

Strong 2025 growth, margin gains, and cash flow, with infant formula recalls impacting Q1 2026.

Q3 2025 delivered +4.8% like-for-like sales growth, driven by volume mix and innovation.

Agile structure, innovation, and targeted M&A drive growth in high protein and medical nutrition.

H1 2025 delivered strong growth, margin gains, and innovation-driven momentum.

Q1 2025 delivered 4.3% like-for-like sales growth, led by health-focused and premium products.

Strong 2024 growth, margin gains, and record cash flow, with robust performance across all regions.

Q3 sales grew +4.2% like-for-like, with strong regional and category performance; guidance confirmed.

Strong H1 2024: 4% like-for-like growth, margin up, cash flow +11%, guidance reiterated.